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Combinationtestingwithanti-HIVElisaandWesternblotisbothsensitiveandspeciﬁcfordiagnosisofestablishedHIV-1infection
but could not detect acute HIV infection (AHI). AHI is a time of extremely high viral load, which may correlate to increased risk
of horizontal or vertical transmission. Thus, early identiﬁcation of AHI could allow for interventions to decrease transmission.
However, recognition of AHI can be challenging as symptoms could be absent or nonspeciﬁc, therefore, AHI is often not detected,
particularlyinpregnancy.WepresentacasereportofAHIinapregnantwomanwhopresentedwithheadacheandfever.Shetested
negative for HIV in the ﬁrst trimester and at time of AHI at 26 3/7 weeks by anti-HIV Elisa, but was diagnosed with AHI based
on an HIV RNA viral load of 434,000 copies/mL. This report presents a case for improved awareness of AHI in pregnancy, and
the need for repeat HIV testing in late pregnancy, and highlighted that early detection of AHI might be possible with adding HIV
RNA testing at time of standard anti-HIV Elisa screening test in pregnancy. Novel laboratory approaches including pooling of sera
for HIV RNA could reduce the cost of HIV RNA testing.
1.CaseReport
A23-year-oldG1P0at26weeksand3daysgestationpresent-
ed to the Emergency Department (ED) at a private hospital
(henceforth referred to as hospital no. 1) complaining of a
headache.Herpastmedicalhistorywassigniﬁcantforchron-
ic hypertension, depression, anxiety, and uterine ﬁbroids.
Her obstetric course had been complicated by intermittent
boutsofabdominalpainsince4weeksofgestation,forwhich
she underwent a diagnostic laparoscopy signiﬁcant only for
a ruptured corpus luteum. She had been a patient of our
teaching institution since early ﬁrst trimester, at which time
all prenatal labs were performed. The only pertinent ﬁndings
were Rh-negative status and Trichomonas vaginalis infec-
tion. HIV Elisa test was negative. At approximately 20 weeks
gestational age, the patient transferred her care from the
teaching institution to a community physician. All prenatal
labs were again repeated; other than an abnormal pap smear,
all labs including HIV antibody test were negative.
Social history obtained upon admission revealed her cur-
rent partner, and father of the baby, was a 50-year-old man
with a history of incarceration, residence in shelters for the
homeless,andpriorhospitalizations forrespiratoryinfection
that was suspicious for tuberculosis. Initial workup of the
mother in the ED at hospital no. 1 revealed elevated liver
enzymes in the range of 400–500’s, leukopenia, and ma-
ternal fever. HIV Elisa was negative and HIV RNA viral load
was ordered. The patient was admitted to the hospital. To
evaluate the patients’ headache, neurology and infectious
disease consults were requested and a lumbar puncture was
performed. VDRL and Cryptosporidium test were ordered
and were negative. The working diagnosis at this time was
disseminated infection with Herpes simplex virus (HSV).
The infectious disease physician recommended intravenous
acyclovir for 10 days. On antiviral therapy day number ﬁve,
the patient requested transfer to another private hospital
(henceforth identiﬁed as hospital no. 2) where her obstetri-
cian had admitting privileges. Of note, HIV viral load was
still pending at time of transfer.
Upon arrival at hospital no. 2, a Maternal-Fetal medicine
specialist from our teaching institution was consulted to
evaluate the presumed disseminated HSV infection. Social2 Case Reports in Infectious Diseases
history in the transferring note received from hospital no.
1 stated that the patient’s partner was currently hospitalized
with renal failure and end-stage AIDS. The plan at this time
was to continue intravenous Acyclovir for the presumed
disseminated HSV infection while HIV workup was in
progress. Repeating HIV rapid screen test, HIV RNA viral
load, and CD4 and CD8 counts were done, a PPD test was
placed, and workup was ordered for elevated liver enzymes.
Consultations with infectious disease and hepatology were
requested. WBC on admission to hospital no. 2 was 4.3;
H e p a t i t i sA ,B ,Cs e r o l o g i e s ,H u m a nG r a n u l o c y t i cE h r l i c h i o -
sis IgG and IgM, and Toxoplasmosis IgG and IGM were
negative. A right upper quadrant ultrasound was performed
and ruled out any pathology. The PPD was read as negative.
Blood cultures were negative. Rapid screen HIV test was
again negative.
Several days after admission to hospital no. 2, laboratory
results were received from hospital no. 1, which were signif-
icant for HIV viral load being greater than 500,000 cop-
ies/mL and CD4 count of 227 cell/mm3. Thus the patient re-
ceivedthenewdiagnosisofacuteHIVinfection.Shewasstart
ed on an antiretroviral regimen of Combivir 150mg/300mg
1 tablet twice daily and Viracept 625mg 2 tablets twice daily.
On hospital day 6, her liver function tests decreased to
an AST of 191, ALT of 365, and an alkaline phosphatase of
111. HIV RNA viral load that was obtained on admission
to hospital no. 2 returned as 434,000 copies/mL. CD4 count
was 323.9 cell/mm3. Her symptoms of fever and headache
resolved and she was later discharged home without further
complications or ﬁndings. Of note, laboratory studies as an
outpatient at approximately 3 weeks later demonstrated a
CD4 count of 447 cell/mm3 and a viral load of 869,000
copies/mL. Antiretroviral therapy was continued as outpa-
tient. At 33 weeks and 5 days gestational age, her CD4 count
was 177 cell/mm3 and viral load was 128 copies/mL.
The patient presented to hospital no. 2 at 37 weeks and 2
days in early labor complicated by chronic hypertension with
superimposed preeclampsia. She was admitted for delivery.
Based on the last viral load being less than 1,000 copies/mL,
she was allowed a trial of vaginal delivery. She received a
loading dose of zidovudine at 2mg/kg followed by main-
tenance dosage of 1mg/kg throughout labor. She also re-
ceived magnesium sulfate for seizure prophylaxis. The viral
loadduringthisadmissionwas74copies/mL.Sheunderwent
a low transverse cesarean section secondary to arrest of dila-
tion and gave birth to a 4 pound 11 ounce infant girl with
Apgar scores of 8 and 9 at one and ﬁve minutes, respectively.
The patient was discharged on postoperative day number
three without complications. The infant was negative for
HIV infection at four months of life.
2. Discussion
Estimates of the incidence of HIV infection in the United
States range from 40,000 to 56,300 annually [1, 2]. At any
time, up to 25% of HIV-infected individuals are unaware of
theirstatus[3].AlthoughtheincidenceofnewHIVinfection
has held relatively steady throughout the 21st century,
improvements in medical management of HIV patients
has led to improved survival, thus the prevalence of the
disease has increased [1]. There are now over 1,000,000 HIV-
infected persons in the United States [1]. Although the total
number of infected persons has increased, the incidence of
new infections remains stable, which indicates a decline in
transmission rates. However, while the incidence does not
appear to have changed signiﬁcantly over the last decade, the
demographics of aﬀected people have changed.
Women are making up a larger proportion of newly
HIV-infected persons than ever before. Initially many HIV-
infected women were intravenous drug users, however in
recent years more women are acquiring HIV through hetero-
sexual contact, many of whom do not have the previously
identiﬁed risk factors for infection [4]. At this time, although
there is more information regarding HIV infection in
pregnant women, data is especially lacking in the detection
and incidence of acute HIV infection in pregnancy. A study
in North Carolina demonstrated the feasibility of identifying
pregnant women with AHI, but due to the study design, it is
impossible to infer AHI incidence among pregnant women
[5].
PregnantwomenhaveanelevatedriskofHIVacquisition
[6, 7]. Even when controlling for behavioral risk factors of
women and their partners, pregnant women have twice the
risk for infection when compared to breastfeeding women
and nonpregnant, nonlactating women [6]. It has been pro-
posed that hormonal changes associated with pregnancy as
well as the impact of these hormones on the vaginal mucosa
account for the increased susceptibility to infection [8–12].
These ﬁndings were further substantiated by another study
that observed a 2-fold increased risk of HIV-1 acquisition
duringpregnancy[6].Therefore,pregnancyisthetimewhen
women are at increased risk for AHI.
Acute HIV-1 infection involves dramatic alterations in
viral load as well as the host’s immune system which may
increase the risk of both horizontal and vertical transmission
during pregnancy [13]. Previous studies have demonstrated
a 10-fold increased risk of horizontal transmission during
AHI as compared to asymptomatic HIV infection [14]. This
could be due to both the elevated viral load and/or the less
frequent use of protective barrier methods as these persons
are not aware of their infected status [4]. Because of the
high viral load, an increase in vertical transmission is a valid
concern if the woman delivers during the stage of acute
infection. This is especially true because medical therapy
and obstetrical interventions aimed at reducing transmission
may not be oﬀered to these women with AHI who are being
misdiagnosed as HIV negative due to the inability to detect
early HIV infection with current standard HIV antibody
testing.
Vertical transmission continues to be of signiﬁcant
concern as the CDC reports HIV infection among infants
to be 144–226 annually in the United States [15]. Lack of
maternalHIVtestinginearlypregnancyandfailuretoreceive
appropriate prophylaxis were commonly cited as the reasons
for these infected infants [15] .T h e r ei sd e ﬁ n i t ec o r r e l a t i o n
between maternal HIV viral load and perinatal transmission
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viral load [17] and high viral load is directly related to an
increased risk of vertical transmission [18], AHI at the time
of delivery could result in increased perinatal transmission
of HIV. There is little data to describe the risk of vertical
transmission in delivery during the acute phase of HIV
infection.
AsacuteHIV-1infectionmaymimicothercommonviral
infections, this disease may be misdiagnosed as in the patient
presented. Furthermore, as there is low prevalence of AHI in
pregnancy in the United States, obstetricians often rely too
much on the negative ELISA antibody test to exclude the dis-
ease.PregnantwomenwhohaveinitialHIV-1screeningdone
before antibody development may have undetected HIV
infection[19].ItisknownthattheantibodytoHIVinfection
does not develop until much later in the disease proc-
ess.TherearecurrentlytwomethodsfordetectingAHI:HIV-
1 RNA by reverse transcriptase polymerase chain reaction
(HIV-1 RNA RT-PCR) and HIV-1 p24 antigen assay. Poly-
merase chain reaction (PCR) can be used to measure the
quantitative plasma HIV-1 RNA level (viral load) by 11-12
days after infection, with a sensitivity close to 100 percent
and a speciﬁcity from 95 to 98 percent [20, 21]. Detection
of AHI by p24 antigen assay is possible as early as 14 to 15
days after infection. However, as p24 antigenemia is short-
lived and declines as immune complexes form and anti-HIV
antibody titers increase, its usefulness is limited [20]. Finally,
antibody seroconversion is apparent from weeks 3 to 7 post-
exposure only [18].
The diagnosis of acute HIV infection can be made with
detection of a quantitative plasma HIV-1 RNA viral load
greater than 50,000 copies/mL coincident with the absence
of HIV antibodies [22]. Our laboratory uses the Cobas
AmpliPrep TaqMan HIV test by Roche which quotes a detec-
tion rate at viral loads as low as 45 copies per mL [23].
Since ELISA antibody screening tests can be falsely negative
in early infections, should these screening tests in pregnancy
be followed by reﬂex RNA viral load testing? This question
becomes especially important because of the ramiﬁcations
of vertical transmission. While p24 antigen assay and HIV-1
RNA RT-PCR are extremely eﬀective means of HIV-1 detec-
tion, their cost prohibits its use as universal screening tools.
As the beneﬁts of detecting AHI in pregnancy appear to
be great, we might consider using HIV-1 RNA RT-PCR
following the initial screening test. To decrease costs, a less
expensive screening method with satisfactory rates of AHI
detection utilizing pooled serum for HIV-1 RNA screening
could be considered [24–26].
When compared to the p24 antigen assay, several studies
demonstrate increased sensitivity as well as lower cost with
pooled serum HIV-1 RNA screening [25, 26] .P C Ro fp o o l e d
sera has comparable sensitivity to single sample PCR, but
with the added beneﬁts of increased test eﬃciency and de-
creased cost of diagnostic screening [25]. In a study in India,
Quinn et al. describe a multistage system of serum pooling
and testing for HIV-1 RNA via reverse-transcriptase poly-
merase chain reaction that was more sensitive for identifying
women with AHI when compared to p24 antigen detection
[26]. It also demonstrated a decreased number of tests
carried out by 78% while decreasing the cost of detecting
individuals with new infections by 34.4% [26]. Furthermore,
thissystembecomesmorecost-eﬀectiveasprevalenceofHIV
infection in the population declines [26]. As such, imple-
mentation of this system in the United States may lessen the
ﬁnancial burden of screening.
Using the serum pooling method, Pilcher et al. estimated
cost of RNA assay at $2 per specimen [27]. Comparatively,
the ﬁnancial burden of caring for a child with perinatally
acquired HIV infection can be extremely high. Wilson et al.
predicted the cost of treatment in the HAART era to be
$1,820 per month in 2007 dollars, with a cost of treatment
over 15 years of $181,436 [28]. In 2009, there were 4,131,019
births in the United States [29]. If all of these births were
singletons carried long enough for the mothers to have
received repeat third trimester HIV screening, we can make a
gross estimate of the additional cost of nationwide screening
with serum pooling method for RNA assay (at $2 per spec-
imen) to be $8.26 million. The cost of 15 years of care of
144 HIV-infected neonates, the low end of the number
of cases of vertical transmission in the US each year, is
$26.13 million. This results in an estimated saving of $17.87
million. While these ﬁgures are gross estimates at best, even
these rudimentary calculations demonstrate the potential for
substantial savings if third trimester screenings were imple-
mented.
In reviewing the literature, we found an important case
report from Steele [30]. He describes three cases of infants
born to mothers with negative HIV screening tests in early
pregnancy. HIV infection in these three women was iden-
tiﬁed shortly after delivery. Two scenarios are plausible: these
womenwere screenedduring the window period of infection
or they became infected later in pregnancy. Two of the three
infants developed HIV infection [30]. This is supported by
one study of 407 HIV-positive mothers which detected eight
seroconversions following negative HIV-1 testing during or
immediately prior to pregnancy, with perinatal HIV trans-
mission following three of these eight sero-conversions [31].
This case report from Steele highlights the importance of
rescreening for HIV infection during pregnancy. Screening
with reﬂex HIV RNA PCR testing and rescreening in late
pregnancy may have detected some if not all of these cases.
Following CDC guidelines, these women were considered to
be low risk and were therefor not retested later in pregnancy
[15, 32]. Again, these women were found to be infected with
HIV after delivery and two of three infants acquired HIV
infection. ACOG guidelines currently recommend ﬁrst tri-
mester care to include routine opt-out HIV-1 screening [33].
High-risk patients, including those residing in 20 states with
high HIV incidence, those who receive prenatal care at
facilities with an HIV incidence of at least 1 per 1000 women
screened, those who exhibit signs or symptoms of acute HIV
infection, and those with high-risk behaviors, qualify for
retesting [15, 32]. While the patient presented in this report
would have been retested for HIV in the third trimester but
most likely with the current standard HIV Elisa screening
test, it is diﬃcult to know if she would have been identiﬁed
if the timing of the test was within the window period (3–7
weeks after exposure) when antibody was not developed yet.
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HIV screening in pregnancy, the question arises: are the
current US screening tests and guidelines adequate?
Reduced perinatal transmission may be achieved with
repeat HIV testing in late pregnancy as well as during labor
and delivery, as recommended by Patterson et al. [5]. How-
ever, while repeat third trimester testing would undoubtedly
identify some newly infected individuals, others could still
be in the window phase. For this reason, further recommen-
dations of reﬂex RNA testing for antibody-negative women
to detect acute HIV infection should be considered [5].
Although this paper focuses on testing in the United States,
several studies have demonstrated the feasibility of reﬂex
RNA testing in developing countries [24–26].
The management of HIV in nonpregnant persons has
been well studied. There are existing guidelines of when and
how to initiate treatment [18]. However, the management
of acute HIV infection is a less well-studied entity. Current
studies indicate that HAART therapy in acute HIV infection
decreasesviremia[34]andthusintheorymayreducevertical
transmission. Unfortunately, there are few studies describing
the impact of AHI in pregnancy (with its high viralload) and
perinatal outcomes. This could be an area of future research.
3. Conclusion
This case study demonstrates the continuing concerns
regarding current HIV screening recommendations during
pregnancy and the diﬃculty of recognizing and diagnosing
acute HIV infection. Obstetricians must be able to recognize
acute HIV infection and should understand how to make
the diagnosis. More research must be done, as there is a
paucity of data describing AHI in pregnancy and its impact
on perinatal outcomes.
This case study reinforces the importance of understand-
ing the timeline of HIV infection from ﬁrst exposure to
development of anti-HIV-1 antibodies and the implications
for early detection of infection. Due to the seronegative
period of acute HIV infection, we support recommendations
for reﬂex viral load testing on all HIV-1 screening in preg-
nancy [5]. The potential increased risk of acquiring HIV
infection during pregnancy due to hormonal change, and
cases where HIV-1 negative women tested in early pregnancy
delivered babies who tested positive shortly after birth also
encourage us to recommend third trimester re-screening of
HIV-1 in all pregnant women regardless of their risk factors
[6, 19]. Additional testing in late pregnancy would allow
women and their unborn children to beneﬁt from inter-
ventions, which reduces vertical transmission of HIV-1.
It is thought that the public health beneﬁts of identifying
HIV-infected patients during acute infection will outweigh
the cost of viral load testing in areas with high HIV trans-
mission [35]. Further cost-beneﬁt studies to assess the appli-
cation of repeat testing in the United States would be illumi-
nating. The increased costs of assessing viral load in addition
to rapid screens may be reduced by using pooled sera
methods of detection. As pointed out by Steele [30]u n l e s s
the CDC revises its guidelines to include repeat HIV screen
ing in late pregnancy and allow for reﬂex viral testing in all
pregnancies, the costs for these tests might not be covered by
insurance companies [30]. We hope that changes in guide-
lines will be initiated soon to eﬀectively detect AHI in preg-
nant women and prevent mother-to-child transmission of
the disease whenever possible.
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